Selected drug interactions in cardiology

1. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme function. Pharmacol Ther 2006; 112 (1): 71–105. doi: 10.1016/j.pharmthera.2006.03.003.

2. Wang Q, Zheng M, Leil T. Investigating transporter-mediated drug-drug intgeractions using a physiologically based pharmacokinetic model of rosuvastatin. CPT Pharmacometrics Syst Pharmacol 2017; 6 (4): 228–238. doi: 10.1002/psp4.12168.

3. Englund G, Hallberg P, Artursson P et al. Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med 2004; 2: 8. doi: 10.1186/1741-7015-2-8.

4. Rengelshausen J, Göggelmann C, Burhenne J et al. Contribution of increased oral bio­availability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarihtromycin interaction. Br J Clin Pharmacol 2003; 56 (1): 32–38. doi: 10.1046/j.1365-2125.2003.01824.x.

5. Tanaka H, Matsumoto K, Ueno K et al. Effect of clarithromycin on steady-state digoxin concentrations. Ann Pharmacother 2003; 37 (2): 178–181. doi: 10.1177/106002800303700202.

6. Juurlink DN, Mamdani M, Kopp A et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289 (13): 1652–1658. doi: 10.1001/jama.289.13.1652.

7. Gomes T, Mamdani M, Juurlink DN. Macrolide-induced digoxin toxicity: a population-based study. Clin Pharmacol Ther 2009; 86 (4): 383–386. doi: 10.1038/clpt.2009.127.

8. Quinn KL, Macdonald EM, Gomes T et al. Macrolides, digoxin toxicity and the risk of sudden death: a population-based study. Drug Saf 2017; 40 (9): 835–840. doi: 10.1007/s40264-017-0539-9.

9. Nademanee K, Kannan R, Hendrickson J et al. Amiodarone-digoxin interaction: Clinical signifikance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol 1984; 4 (1): 111–116. doi: 10.1016/s0735-1097 (84) 80327-7.

10. Study INT5189. In: U.S. Food and Drug Administration; Center for Drug Evaluation and Research. NDA 22-425 Clinical Pharmacology and Biopharmaceutics Review: 230–236.

11. Hohnloser SH, Halperin JL, Camm AJ et al. Interaction between digoxin and dronedarone in the PALLAS trial. Circ Arrhythm Electrophysiol 2014; 7 (6): 1019–1025. doi: 10.1161/CIRCEP.114.002046.

12. Belz GG, Doering W, Munkes R et al. Interaction between digoxin and calcium antagonists and antiarrhythmic drugs. Clin Pharmacol Ther 1983; 33 (4): 410–417. doi: 10.1038/clpt.1983.55.

13. Salerno DM, Granrud G, Sharkey P et al. A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexes. Am J Cardiol 1984; 53 (1): 77–83. doi: 10.1016/0002-9149 (84) 90687-8.

14. Pedersen KE, Dorf-Pedersen A, Hvidt S et al. The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects. Eur J Clin Pharmacol 1982; 22 (2): 123–127. doi: 10.1007/BF00542456.

15. SPC v ČR. Isoptin (verapamil), Mylan, 2020/4. Dostupné na: //www.sukl.cz/modules/medication/search.php.

16. Baris N, Kalkan S, Güneri S et al. Infuence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? Eur J Clin Pharmacol 2006; 62 (7): 535–538. doi: 10.1007/s00228-006-0138-7.

17. Ratnapalan S, Griffiths K, Costei AM et al. Digoxin carvedilol interactions in children. J Pediatr 2003; 142 (5): 572–574. doi: 10.1067/mpd.2003.160.

18. SPC v ČR. Atram (karvedilol), Zentiva, 2018/6. Dostupné na: http: //www.sukl.cz/modules/medication/search.php.

19. Partanen J, Jalava KM, Neuvonen PJ. Intraconazole increasses serum digoxin concentration. Pharmacol Toxicol 1996; 79 (5): 274–276. doi: 10.1111/j.1600-0773.1996.tb00273.x.

20. Jalava KM, Partanen J, Neuvonen PJ. Intraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997; 19 (6): 609–613. doi: 10.1097/00007691-199712000-00001.

21. Steiness E. Renal tubular secretion of digoxin. Circulation 1874; 50 (1): 103–107. doi: 10.1161/01.cir.50.1.103.

22. Waldorf S, Andersen JD, Heeboll-Nielsen N et al. Spironolactone-induced changes in digoxin kinetics. Clin Pharmacol Ther 1978; 24 (2): 162–167. doi: 10.1002/cpt1978242162.

23. Dorian P, Strauss M, Cardella C et al. Digoxin-cyclosporine interaction: severe digitalis toxicity after cyclosporine treatment. Clin Invest Med 1988; 11 (2): 108–112.

24. Woosley RL, Heise CW, Romero KA. QTdrugs List, (1. 3. 2020), AZCERT, Inc., 1822 Innovation Park Dr., Oro Valley, AZ 85755, USA. Available at: www.CredibleMeds.org.

25. Boutitie F, Boissel JP, Connolly SJ et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European myocardial infarct amiodarone trial) and CAMIAT (Canadian amiodarone myocardial infarction trial) databases. The Emiat and Camiat Investigators. Ciculation 1999; 99 (17): 2268–2275. doi: 10.1161/01.cir.99.17.2268.

26. SPC ČR. Cordarone^® (amiodaron), sanofi-aventis, 2019/8. Dostupné na: http: //www.sukl.cz/modules/medication/search.php)

27. Bultas J. Antiarytmika. In: Suchopár J et al. Compendium Léčiva používaná v podmínkách ČR, 2018: 1125–1132.

28. Sanoski CA, Bauman JL. Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. Chest 2002; 121 (1): 19–23. doi: 10.1378/chest.121.1.19.

29. Holm J, Lindh JD, Andersson ML et al. The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population. J Thromb Haemost 2017; 15 (3): 446–453. doi: 10.1111/jth.13614.

30. Santos PC, Soares RA, Strunz CM et al. Simultaneous use of amiodarone influences warfarin maintenance dose but is not associated with adverse events. J Manag Care Spec Pharm 2014; 20 (4): 376–381. doi: 10.18553/jmcp.2014.20.4.376.

31. Lu Y, Won KA, Nelson BJ et al. Characteristics of the amiodarone-warfarin interaction during long-term follow-up. Am J Health Syst Pharm 2008; 65 (10): 947–952. doi: 10.2146/ajhp060415.

32. Lam J, Gomes T, Juurlink DN et al. Hospitalization for hemorrhage among warfarin recipients prescribed amiodarone. Am J Cardiol 2013; 112 (3): 420–423. doi: 10.1016/j.amjcard.2013.03.051.

33. Suchý D, Poklopová Z. Lékové interakce warfarinu s kardiovaskulárními léky. Klin Farmakol Farm 2005; 19: 40–42.

34. Chang SH, Chou IJ, Yeh YH et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017; 318 (13): 1250–1259. doi: 10.1001/jama.2017.13883.

35. Mendell J, Zahir H, Matsushima N et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013; 13 (5): 331–342. doi: 10.1007/s40256-013-0029-0.

36. SPC ČR. Pradaxa^® (dabigatran), Behringer Ingelheim 2020/1. Dostupné na: https: //www.ema.europa.eu/en/documents/productinformation/pradaxa-epar-product-information_cs.pdf.

37. Hanigan S, Das J, Pogue K et al. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis 2020; 49 (4): 636–643. doi: 10.1007/s11239-020-02037-3.

38. Senesael AL, Larock AS, Douxfils J et al. Rivaroxaban plasma levels in patients admitted for bleed­ing events: insights from a prospective study. Thromb J 2018; 16: 28. doi: 10.1186/s12959-018-0183-3.

39. Stölberg C, Bastovansky A, Finsterer J. Fatal intracerebral bleeding under rivaroxaban. Int J Cardiol 2015; 201: 110–112. doi: 10.1016/j.ijcard.2015.06.081.

40. Oladiran O, Segal J, Nwosu I et al. A rare case of spontaneous cardiac tamponade idnuced by concomitant use of rivaroxaban and amiodarone. Case Rep Cardiol 2018; 1650716. doi: 10.1155/2018/1650716.

41. SPC ČR. Xarelto^® (rivaroxaban), Bayeer 2020/1. Dostupné na: https: //www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_cs.pdf.

41. Flaker G, Lopez RD, Hylek E et al. Amiodarone, anticoagulation and clinical events in patients with atrial fibrillation. Insights from the ARISTOTLE trial. J Am Coll Cardiol 2014; 64 (15): 1541–1550. doi: 10.1016/j.jacc.2014.07.967.

42. Gulilat M, Keller D, Linton B et al. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. J Trhomb Thrombolysis 2020; 49 (2): 294–303. doi: 10.1007/s11239-019-01962-2.

43. SPC ČR. Eliquis^® (apixaban), Bristol-Myers Squib/Pfizer, 2020/3. Dostupné na: https: //www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_cs.pdf.

44. Steffel J, Guigliano RP, Braunwald E et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 Trial. Eur Heart J 2015; 36 (33): 2239–2245. doi: 10.1093/eurheartj/ehv201.

45. SPC ČR. Lixiana^® (edoxaban), Daiichi Sankyo, 2020/3. Dostupné na: https: //www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_cs.pdf.

46. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004; 94 (9): 1140–1146. doi: 10.1016/j.amjcard.2004.07.080.

47. Patel AM, Shariff S, Bailey DG et al. Statin toxicity from macrolide antibio­tic coprescription: a population-based cohort study. Ann Intern Med 2013; 158 (12): 860–876. doi: 10.7326/0003-4819-158-12-201306180-00004.

48. Li DQ, Kim R, McArthur E. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. CMAJ 2015; 187 (3): 174–180. doi: 10.1503/cmaj.140950.

49. SPC ČR. Simvastatin Mylan (simvastatin), Mylan, 2020/2n. Dostupné na: http: //www.sukl.cz/modules/medication/search.php.

50. SPC ČR. Sortis (atorvastatin), Pfizer, 2019/9. Dostupné na: http: //www.sukl.cz/modules/medication/search.php).

51. SPC ČR. Crestor (rosuvastatin), AstraZeneca AB, 2019/4. Dostupné na: http: //www.sukl.cz/modules/medication/search.php.

52. SPC ČR. Lescol XL (fluvastatin), Novartis, 2018/12. Dostupné na: http: //www.sukl.cz/modules/medication/search.php.

53. Khandwala MH. Lipid lowering inefficiacy of high-dose statin therapy due to concurrent use of phenytoin. South Med J 2006; 99 (12): 1385–1387. doi: 10.1097/01.smj.0000251470.39036.ea.

54. Candrilli SD, Manjunath R, Davis KL et al. The association between antiepileptic drugs and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy. Epilepsy Res 2010; 91 (2–3): 260–266. doi: 10.1016/j.eplepsyres.2010.07.021.

55. Mäkinen J, Rainesalo S, Raitanen J et al. Discontinuation of carbamazepine due to concerns of long-term consequences of enzyme induction. Epilepsia Open 2018; 3 (3): 340–347. doi: 10.1002/epi4.12227.

56. Al-Sarraf A, Li M, Frohlich J. Statin resistant dyslipidemia in a patient treated with amiodarone. BMJ Case Rep 2011; bcr0820114620. doi: 10.1136/bcr.08.2011.4620.

57. Hudig F, Bakker O, Wiersinga WM. Amiodarone decreases gene expression of low-density lipoprotein receptor at both the mRNA and the protein level. Metabolism 1998; 47 (9): 1052–1057. doi: 10.1016/s0026-0495 (98) 90277-3.